Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors

Impact of Interferon‐Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV‐ and HCV‐Coinfected Patients

(2010) Aarthi Chary et al.   JOURNAL OF INFECTIOUS DISEASES

Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus

(2010) L. Rong et al.   Science Translational Medicine

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

(2009) Simone Susser et al.   HEPATOLOGY

Temporal Dynamics of a Predominant Protease Inhibitor–Resistance Mutation in a Treatment-Naive, Hepatitis C Virus–Infected Individual

(2009) Arthur Y. Kim et al.   JOURNAL OF INFECTIOUS DISEASES

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

(2008) Thomas Kuntzen et al.   HEPATOLOGY

Preexisting Resistance to Nonnucleoside Reverse‐Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz‐Based Regimen in Treatment‐Naive HIV‐1–Infected Subjects

(2008) Daniel R. Kuritzkes et al.   JOURNAL OF INFECTIOUS DISEASES

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects

(2008) Doug J. Bartels et al.   JOURNAL OF INFECTIOUS DISEASES

Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

(2007) Maria Cubero et al.   VIROLOGY